Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

A registered dietitian shares the best diet and exercise tips to help optimize your GLP-1 response for faster weight loss.

About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...

Ozempic, Wegovy and Mounjaro are often the most popular weight loss drugs. While these medications help people lose weight, ...

KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...